AbbVie, Parkinson's disease
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson’s disease. Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease.
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy.
AbbVie Parkinson's disease therapy hits main goal in late-stage trial
AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease. Read more here.
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday. Patients showed a statistically significant improvement when two fixed doses of the drug,
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease
Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a
AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study
AbbVie on Thursday said a late-stage study of its recently acquired tavapadon drug candidate for the neurodegenerative disorder Parkinson's disease hit its key goals. AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial,
AbbVie Inc. stock rises Thursday, still underperforms market
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
Abbvie Worker Advances Suit Over Family Medical History Queries
Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...
Outsourcing-pharma21h
AbbVie announces positive phase 3 results for Parkinson’s drug
These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.
clinicaltrialsarena1d
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials
AbbVie has revealed positive data from a post-hoc analysis of Phase III trials of RINVOQ in treating atopic dermatitis (AD).
bovnews1d
ABBV’s Latest Twist: What’s Fueling the Unexpected Shifts in AbbVie Inc’s Stock Price?
AbbVie Inc (ABBV) stock saw a decline, ending the day at $193.51 which represents a decrease of $-0.32 or -0.17% from the prior close of $193.83. The stock opened at $192.95 and touched a low of $191.
Hosted on MSN3d
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
AbbVie Inc. (NYSE:ABBV) is largely controlled by institutional shareholders who own 73% of the company
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...